Estrella Immunopharma Reports Positive STARLIGHT-1 Trial Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 09 2026

0mins

ESLA+2.91%

Should l Buy ESLA?

Source: Newsfilter

Clinical Trial Results: Estrella presented positive results from the STARLIGHT-1 trial at the 2026 ASTCT & CIBMTR meetings, where EB103 achieved a 100% complete response rate in the high-dose cohort, highlighting its potential in treating aggressive B-cell Non-Hodgkin Lymphoma.
Sustained Patient Responses: All patients who achieved a complete response maintained their status at the data cutoff, with response durations ranging from 3 to 18 months, indicating EB103 may offer durable treatment effects for high-risk patients.
Safety Profile: To date, the STARLIGHT-1 trial has reported no treatment-related serious adverse events, reinforcing EB103's potential as a

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ESLA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ESLA

About ESLA

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Estrella Immunopharma Receives Coverage from Zacks

Mar 23 2026Newsfilter

Zacks Coverage Initiation: Zacks Small-Cap Research has initiated coverage on Estrella Immunopharma, assigning a $12.00 per share valuation, highlighting the differentiation of its ARTEMIS platform and promising early clinical data, which may boost investor confidence.
Clinical Trial Results: In the STARLIGHT-1 trial, all five evaluable patients achieved a 100% complete response rate at Month 1 among the nine patients, with no treatment-related serious adverse events reported, indicating EB103's potential in high-risk patients.
Safety Profile Advantage: EB103 demonstrated a more favorable safety profile compared to existing CAR-T therapies in the Phase I trial, with all patients experiencing only low-grade Cytokine Release Syndrome (CRS) and no instances of Grade 3 or higher CRS, suggesting its clinical viability.
ARTEMIS Platform Innovation: Zacks SCR describes the ARTEMIS platform as a potential next-generation evolution, emphasizing its ability to achieve more controlled T-cell activation through an antibody-TCR architecture, which may enhance Estrella's competitiveness in CAR-T innovation.